Macitentan denied for failing step therapy by Aetna?

Aetna's specific coverage criteria for macitentan are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Requires Step Therapy for Macitentan — and Why You Can Appeal

Macitentan is an oral endothelin receptor antagonist (ERA) approved for pulmonary arterial hypertension (PAH). Aetna's step-therapy requirement typically means the plan wants evidence that a patient has tried one or more other PAH therapies — often a different ERA or another drug class — before approving macitentan. This protocol is designed to manage cost, but it can conflict with individualized clinical care, particularly for patients whose disease course or tolerability profile makes the required step drugs inappropriate.

## Why Step-Therapy Denials Are Appealable

Step-therapy denials are among the most commonly overturned on appeal, because the medical record often already documents the required prior therapy, or the prescriber can demonstrate a clinical reason why the step drug is contraindicated or unsuitable for this specific patient. Many states have also enacted step-therapy reform laws requiring insurers to grant exceptions when a step drug is likely to cause adverse effects, is clinically inappropriate, or the patient has already tried and failed it.

## Federal Appeal Framework

• Internal appeal: Initiate an internal appeal within the window stated in your denial notice. Include a step-therapy exception request alongside the appeal if Aetna's plan documents provide for one.
• External review (ACA §2719): After exhausting internal appeals, non-grandfathered plan members may request independent external review, generally within four months of the final denial.
• ERISA §503: Employer-sponsored plan members have the right to a full-and-fair review of all adverse benefit determinations.
• Expedited review: Available when standard timelines would seriously jeopardize health; insurers must respond within 72 hours.

## Documentation to Gather

• Prior therapy records: Chart notes, pharmacy records, and any discontinuation summaries for every PAH therapy previously tried, with exact dates and documented outcomes or adverse effects.
• Diagnosis and disease severity: Current functional classification, hemodynamic data from right heart catheterization, and specialist assessment of disease trajectory.
• Prescriber medical-necessity letter: A detailed letter from your PAH specialist explaining why macitentan is the appropriate choice for this patient, why each required step drug is not appropriate (inadequate response, intolerance, or contraindication per the FDA label), and how the prescription aligns with current specialty society guidelines.
• Applicable guidelines: Reference to current recommendations from the relevant pulmonary hypertension specialty organizations supporting the prescribed agent.

## Criteria-Mapping Structure

Obtain Aetna's current published clinical policy and step-therapy criteria for PAH medications. Then map each requirement to the exact evidence in the chart:

| Step-Therapy Requirement | Chart / Documentation Response | |---|---| | Trial of required prior agent(s) | [Dates, drug names, outcomes per pharmacy/chart records] | | Documented failure or intolerance | [Prescriber note, date, specific reason] | | Exception criteria met (if applicable) | [State law / plan exception language + clinical basis] | | Current diagnosis and indication | [ICD code, specialist note confirming PAH] |

A well-organized appeal that walks the reviewer through each criterion reduces the chance of a secondary denial on procedural grounds.